Eyewire News: The Podcast
12.11.24
New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices
View full description +
Subscribe
01.07.26
Staar Terminates Merger with Alcon12.31.25
2025 Year in Review - Part 212.24.25
2025 Year in Review - Part 112.17.25
Update on Reproxalap PDUFA Timing11.18.25
Live Coverage of B+L Investor DayShow More